Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 9 Plasma cell 6 Other hematologic neoplasm 5 Genitourinary 3 Tumor-Agnostic 2 Thoracic 2 Sarcoma 1 Other 1 Myeloid 1 Head & Neck 1 Gynecologic 1 Gastrointestinal 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 315 Radiotherapy 139 Cetuximab 133 pembrolizumab 131 Docetaxel 122 Carboplatin 119 Radiotherapy, Intensity-Modulated 97 Fluorouracil 94 Paclitaxel 92 Nivolumab 64 Gemcitabine 50 toripalimab 46 Radiation 44 Drug Therapy 39 Capecitabine 39 Magnetic Resonance Spectroscopy 38 Surgical Procedures, Operative 33 camrelizumab 31 130-nm albumin-bound paclitaxel 29 apatinib 27 tislelizumab 26 Chemoradiotherapy 26 Specimen Handling 25 Bevacizumab 24 durvalumab 23 Albumin-Bound Paclitaxel 23 nimotuzumab 22 lenvatinib 21 Sorafenib 21 Platinum 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Diphenhydramine × Head & Neck × Clear all

NCT03107182 2025-05-06

OPTIMA-II

University of Chicago

Phase 2 Completed

72 enrolled 14 charts

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon ⚡